Yayıncı "Future Medicine Ltd" için listeleme

Toplam kayıt 3, listelenen: 1-3

    • In Vitro And In Vivo Fitness Costs Associated With Mycobacterium Tuberculosis Rpob Mutation H526D 

      Rifat, Dalin; Campodnico, Victoria L.; Tao, Jing; Miller, James A.; Alp, Alpaslan; Yao, Yufeng; Karakousis, Petros C. (Future Medicine Ltd, 2017)
      Aim: There is controversy regarding the potential fitness costs of rifampicin (RIF) resistance-conferring mutations in the Mycobacterium tuberculosis (Mtb) rpoB gene. We characterized the pathogenicity of an Mtb RpoB H526D ...

    • Oligonucleotide-Based Theranostic Nanoparticles In Cancer Therapy 

      Shahbazi, Reza; Ozpolat, Bulent; Ulubayram, Kezban (Future Medicine Ltd, 2016)
      Theranostic approaches, combining the functionality of both therapy and imaging, have shown potential in cancer nanomedicine. Oligonucleotides such as small interfering RNA and microRNA, which are powerful therapeutic ...

    • Personalized Treatment is Better Than One Treatment Fits All in the Management of Patients with Mcrc: A Consensus Statement 

      Yalcin, Suayib; Trad, Diaeddine; Kader, Yasser Abdel; Halawani, Hafez; Demir, Osman Gokhan; Mall, Riaz; Meshcheryakov, Andrey; Nasr, Fadi; Nosworthy, Adam; Osinsky, Dmitry; Tumanova, Assel; Turhal, Serdar; Tejpar, Sabine; Koehne, Claus-Henning (Future Medicine Ltd, 2014)
      The VEGF- (bevacizumab) and EGFR- (cetuximab and panitumumab) targeting monoclonal antibodies have become integral components of the first-line treatment strategies for patients with metastatic colorectal cancer (mCRC). ...